SCHEMBL8911487

SCHEMBL8911487

COC(=O)C1CC(=O)c2ccccc2C1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
BUB1 O43683 2/20 0.48
CYP19A1 P11511 1/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
RAB9A P51151 1/20 0.44
ACHE P22303 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
DRD2 P14416 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
TSHR P16473 2/20 0.39
BRD4 O60885 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ITGA4 P13612 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15519819 1.00 KMT2A (0.56) KMT2ABUB1CYP19A1ALDH1A1KDM4E
SCHEMBL29519648 0.84 KMT2A (0.54) KMT2ABUB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL857083 0.84 KMT2A (0.54) KMT2ABUB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL9344657 0.83 ALDH1A1 (0.61) KMT2AALDH1A1KDM4ETSHRMAPT
SCHEMBL17540272 0.83 KMT2A (0.44) KMT2ABUB1ALDH1A1RAB9AACHE
SCHEMBL15116647 0.81 ACHE (0.46) CYP19A1ALDH1A1RAB9AACHESMN1; SMN2
SCHEMBL30834248 0.80 KMT2A (0.52) KMT2ABUB1ALDH1A1KDM4EACHE
SCHEMBL7034883 0.80 KMT2A (0.52) KMT2ABUB1ALDH1A1KDM4EACHE
SCHEMBL7818824 0.80 KMT2A (0.43) KMT2ABUB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL7818827 0.80 KMT2A (0.43) KMT2ABUB1ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2962992-B1 FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF LG CHEMICAL LTD (KR) 2021-07-07 EP disclosed
US-9923143-B2 Fullerene derivative, organic solar cell using same, and manufacturing method thereof LG CHEM, LTD. (KR) 2018-03-20 US disclosed
US-9923143-B2 Fullerene derivative, organic solar cell using same, and manufacturing method thereof LG CHEM, LTD. (KR) 2018-03-20 US disclosed
US-20170137371-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2017-05-18 US disclosed
US-20170137371-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2017-05-18 US disclosed
US-20170137371-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2017-05-18 US disclosed
US-9598371-B2 Arylalkylamine compounds as calcium sensing receptor modulators LUPIN ATLANTIS HOLDINGS SA (CH) 2017-03-21 US disclosed
US-9598371-B2 Arylalkylamine compounds as calcium sensing receptor modulators LUPIN ATLANTIS HOLDINGS SA (CH) 2017-03-21 US disclosed
US-9598371-B2 Arylalkylamine compounds as calcium sensing receptor modulators LUPIN ATLANTIS HOLDINGS SA (CH) 2017-03-21 US disclosed
US-20160075655-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2016-03-17 US disclosed
US-9227919-B2 Arylalkylamine compounds as calcium sensing receptor modulators LUPIN LIMITED (IN) 2016-01-05 US disclosed
US-20150239827-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2015-08-27 US disclosed
US-20150239827-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2015-08-27 US disclosed
EP-2888225-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS Lupin Limited (IN) 2015-07-01 EP disclosed
WO-2014033604-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN LIMITED (IN) 2014-03-06 WO disclosed
WO-2014033604-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN LIMITED (IN) 2014-03-06 WO disclosed
US-20090291998-A1 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF EISAI R&D MANAGEMENT CO., LTD. 2009-11-26 US disclosed
US-7524883-B2 Eponemycin and epoxomicin analogs and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
US-5639902-A FOR TREATING PSORIASIS ADIR ET COMPAGNIE (FR) 1997-06-17 US disclosed
WO-1988004292-A1 ANTIPSYCHOTIC AMINO-POLYHYDRO-BENZ-(ISO)QUINOLINES AND INTERMEDIATES THE UPJOHN COMPANY (US) 1988-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291998-A1 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF PSMC4, PSMB6, EPOR KMT2A 1219/4885BUB1 1467/4885CYP19A1 768/4885
US-20170137371-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS CASR, RYR2, ORAI1 KMT2A 3280/4885BUB1 3398/4885CYP19A1 2086/4885
US-20150239827-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS CASR, RYR2, ORAI1 KMT2A 3280/4885BUB1 3398/4885CYP19A1 2086/4885
US-20160075655-A1 ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS CASR, RYR2, ORAI1 KMT2A 3280/4885BUB1 3398/4885CYP19A1 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.